Loading clinical trials...
Loading clinical trials...
The aim of the trial is to improve efficacy of nivolumab in patients with relapsed or refractory HL who recently progressed on anti-PD1 therapy. Nivolumab is highly effective and well tolerated in rrHL, nevertheless CR-rates are low and a considerable proportion of patients suffers from progressive disease. Localized RT induces an immunogenic effect which might work synergistically and facilitate augmented systemic (i.e. abscopal) responses in combination with nivolumab.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
1st Department of Medicine, Cologne University Hospital
Cologne, Germany
Start Date
December 5, 2019
Primary Completion Date
May 4, 2024
Completion Date
May 4, 2025
Last Updated
April 3, 2025
26
ACTUAL participants
Nivolumab plus radiotherapy
OTHER
Lead Sponsor
University of Cologne
NCT07356882
NCT05362773
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06848569